From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma

Yaojie Fu 1, Shanshan Liu 1,2, Shan Zeng 1,3 and Hong Shen 1,2*

Abstract
Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in HCC treatment, less than 40% of HCC patients are eligible for potentially curative therapies. Recently, cancer immunotherapy has emerged as one of the most promising approaches for cancer treatment. It has been proven therapeutically effective in many types of solid tumors, such as non-small cell lung cancer and melanoma. As an inflammation-associated tumor, it’s well-evidenced that the immunosuppressive microenvironment of HCC can promote immune tolerance and evasion by various mechanisms. Triggering more vigorous HCC-specific immune response represents a novel strategy for its management. Pre-clinical and clinical investigations have revealed that various immunotherapies might extend current options for needed HCC treatment. In this review, we provide the recent progress on HCC immunology from both basic and clinical perspectives, and discuss potential advances and challenges of immunotherapy in HCC.

Keywords: Hepatocellular carcinoma (HCC), Immunotherapy, Oncolytic virus, Immune checkpoint blockade (ICB), Adoptive cell transfer

Background
Hepatocellular carcinoma (HCC) represents the most common type of primary liver cancer, with a global incidence of 500,000 new cases per year [1]. HCC is closely associated with chronic liver inflammation and some well-known risk factors, including chronic HBV and HCV infections, alcohol consumption, diabetes mellitus and several metabolic diseases [2]. The current therapeutic options available for HCC, such as transarterial chemoembolization (TACE), radiofrequency ablation, surgical resection and transplantation, are only curative for some patients in early stages. Other more effective approaches emerged in the past few years, such as tyrosine kinase inhibitors (TKIs) targeting angiogenesis (e.g. Sorafenib, lenvatinib, regorafenib) [3], clinically tested selective Cyclin dependent kinase 5 and 4/6 (Cdk5, Cdk4/6) inhibitors (Dinaciclib & Palbociclib) [4–6], and highly selective fibroblast growth factor receptor 4 (FGFR4) inhibitor H3B-6527 [7, 8], which pre-clinically and clinically show encouraging efficacy and have been rigorously pursued for advanced HCC.

The liver is a ‘tolerogenic’ organ that can arouse its immune responses to prevent undesirable pathogen attack and tumor initiation. However, as a typical inflammation-linked tumorigenesis, immune evasion is one of the features occurring during the initiation and evolution of HCC [9]. A number of immune suppressor mechanisms, including intratumoral accumulation of immunosuppressive cell populations, defective antigen presentation and activation of multiple inhibitory receptor-ligand pathways, favor tolerance over immunity, and promote progression of HCC [10, 11]. The magnitude of immune suppression in the tumor microenvironment (TME) is closely correlated with...
poor prognosis in HCC patients. Hence, for better arousing anti-tumor immunity, more details about suppressed immune landscape of HCC urgently needs to be elucidated.

The intricate immune network in TME of HCC

The HCC tumor microenvironment (TME) is a dynamic system, which comprises cancer cells, the intricate cytokine environment, extracellular matrix, immune cell subsets and other components [12]. It’s well established that the immune landscape of HCC has a strong suppressor feature. In this complex network, the pro-tumorigenic immune response, mediated by diverse immunosuppressive cell subsets, secretions and signaling, plays a pivotal role in driving immune evasion [13] (Fig. 1). Moreover, ‘fatigue’ of anti-tumor immunity also contributes to tumor tolerance and progression. Here, we discuss new advances in the immunosuppressive picture of HCC.

Representative immunosuppressive components in TME of HCC

Myeloid-derived suppressor cells (MDSCs)

MDSCs is a heterogeneous population of immature myeloid cells (IMCs), which are expanded in pathological conditions and up-regulate expression of immune suppressive factors, such as arginase and inducible nitric oxide synthase (iNOS or NOS2) [14]. Various tumor originated cytokines, such as G-CSF, GM-CSF, VEGF, MCP-1 and IL-1β, have been demonstrated to induce MDSCs infiltration [15]. Cell cycle related kinase (CCRK) represents a novel signaling target for cancer immunotherapy [16]. Emerging evidence also indicates the hepatoma-intrinsic CCRK upregulates interleukin-6 (IL-6) production through EZH2/NF-κB signaling, which consequently induce MDSCs accumulation in TME [17]. Hepatic carcinoma related tumor-associated fibroblasts (TAFs), a stromal part in HCC, can induce peripheral blood monocyte migration and differentiation into CD14

Fig. 1 The landscape of immunosuppressive tumor microenvironment of HCC. Diverse suppressive immune cell subsets infiltration, regulatory secretions and some inhibitory signaling mediate HCC immune evasion. (Notes: Tregs: regulatory T cells; TAMs: tumor-associated macrophages; TANs: tumor associated neutrophils; CTLs: cytotoxic T lymphocytes; CAF: cancer associated fibroblast; MDSCs: myeloid-derived suppressor cells; HSCs: hepatic stellate cells; NK: natural killer cell; KC: Kupffer cell)
As a powerful inhibitory immune modulator, infiltrated MDSCs in HCC damage effector T cells, expand immune checkpoint signaling, decrease NK cell cytotoxicity and cytokine production by diverse mechanisms [21, 22]. The MDSCs in fibrotic HCC tissue are notably correlated with reduced tumor infiltrating lymphocytes (TILs) and elevated tumorigenicity, aggressive phenotype, moreover, whose activation and infiltration contribute greatly to worse survival rate both in mouse model and HCC patients [23]. CD14+ HLA-DR−/low MDSCs can blunt HCC immunity through inducing activation of CD4+ CD25+ Foxp3+ regulatory T cells, inhibiting proliferation and IFN-γ secretion of CD3/CD28-stimulated autologous peripheral blood mononuclear cells (PBMCs) [24]. T cell function is impaired due to competition for energy resources (e.g. arginine and cysteine) with MDSCs [25], as well as involvement of several inhibitory receptor-ligand pathways in MDSCs-mediated immune evasion. Tumor-derived TGF-β triggers recruitment of MDSCs in a CXCL1/2/5- and CXCR2-dependent manner. The infiltrated MDSCs selectively suppress IFN-γ production deriving from NKT cells [26]. MDSCs also can express galectin-9 that binds to TIM-3 on T cells, inducing T-cell apoptosis [27]. In addition, it’s suggested that MDSCs in advanced HCC patients may interact with Kupffer cells to induce PD-L1 expression, and mediate inhibited cytotoxicity and cytokine release of NK cells through the Nkp30 receptor [28]. Taken together, MDSCs exert versatile immunosuppressive effects in HCC. Combined treatment with anti-PD-1/PD-L1 and concomitant targeting MDSCs (such as CCRK inhibition or p38 MAPK inhibitor) may synergistically enhance efficacy to eradicate HCC [17, 23]. In addition, recent evidence suggests radiation and IL-12 combination therapy (RT/IL-12) may elevate anti-tumor immunity in HCC by reducing MDSCs accumulation and the production of reactive oxygen species (ROS) [29]. Hence, MDSCs may serve as a potential target for resetting immunotolerant state in HCC tumors.

**Tumor-associated macrophages (TAMs)**

Macrophages arise from bone marrow-derived circulating monocytes, and then reside in normal tissues. The two polarizing phenotypes M1 and M2, are highly plastic in response to complex stimuli. Substantial clinical data and experimental research confirmed that alternatively activated status macrophages, the M2 phenotype, stimulate tumor initiation, progression and malignant metastasis by various mechanisms [30, 31]. In HCC, some specific populations of the immunosuppressive tumor-associated macrophages (TAMs) have emerged as a research hotspot recently. The well-identified HCC-derived cytokines, such as IL-4, IL-13, CSF-1, CCL2, CXCL12, connective tissue growth factor (CTGF) [32–34], induce TAMs differentiation from CCR2+ inflammatory monocytes, alternatively activated macrophages (AAMs) infiltration, then reduce innate or adaptive immunity [34, 35]. Osteopontin (OPN) expressed by HCC cells not only has a positive association with PD-L1 expression in HCC, moreover, it facilitates alternative activation and chemotactic migration of TAMs via CSF1-CSF1R pathway in TAMs [36]. HCC cells originated HIF-1α has been recently suggested to enhance IL-1β release by TAMs via TLR4/TRIF/NF-κB signaling pathway, which fosters EMT and immune evasion of HCC [37]. Crosstalk between MDSCs and TAMs results in decreased production of IL-6, IL-12, down-expression of MHCII, and elevated production of IL-10, a strong inhibitory mediator that impairs downstream CD8+ T cell and NK cell cytotoxicity [38]. TAMs-derived IL-10 also increases intratumoral Foxp3+ Tregs frequency, which then suppresses CD4+CD25+ T cells activation [38, 39]. TAMs in the peritumoral stroma of HCC have been shown to secrete multiple key proinflammatory cytokines (e.g. IL-1β, IL-6, IL-23, and TNF-α) and contribute to the expansion of interleukin-17-producing CD4+ T helper 17 cells (Th17), which suppress anti-tumor immunity by over-expressing several activation markers, such as PD-1, CTLA-4, and GITR [40]. In addition, TAMs are highly involved in other immune inhibitory regulations [41, 42]. TGF-β in the TME of HCC promotes the Tim-3 expression on TAMs, subsequently enabling the activated TAMs to facilitate tumor growth and immune tolerance via NF-κB signaling and downstream IL-6 production [43]. TAMs derived IL-6/STAT3 signaling also has been validated to sustain HCC carcinogenesis by promoting its carcinoma stem cells (CSCs)-like characteristics [44].

Notably, recent evidence indicates that PD-1+ TAMs can capture anti-PD-1 monoclonal antibodies (aPD-1 mAbs) through Fcy receptors (FcyRs) expressed on the surface binding to drug’s Fc domain glycan [45]. This novel investigation indicates that blockade of FcyRs before aPD-1 mAbs administration may substantially improve checkpoint blockade therapy.

**Tumor associated neutrophils (TANs)**

Heterogeneity of TANs is a fundamental property that allows TANs to perform corresponding functions for...
adaptations to changing microenvironment. Similar to macrophages, neutrophils differently affect tumor biological behaviors depending on their polarization, either anti-tumoral (N1) and pro-tumoral (N2) phenotypes [46]. In some solid tumor models, such as lung cancer, metastatic renal cell cancer (mRCC) and melanoma, it was previously reported that TANs infiltration or neutrophil-lymphocyte ratio (NLR) closely correlate with tumor progression, which can serve as a significant predictor for monitoring patients with advanced tumor receiving anti-PD-1/PD-L1 immunotherapy [47, 48]. TANs activation is modulated by cytokines, such as Type I interferons (IFNs) and TGF-β. TANs mainly suppress anti-tumor immunity via interacting with CD8+ T cells, inducing CD8+ T cells apoptosis through nitric oxide (NO) production mediated by tumor necrosis factor-α (TNF-α) [50].

The facilitator role of TANs in pathological progression of HCC has become a topic of growing interest in recent years. Clinically, TANs play a key role in driving progression and poor prognosis of HCC, and NLR is an independent predictor of survival after hepatectomy in patients with HCC [51, 52]. The newest discovery shows that loss of hypoxia associated factor, HAF (encoded by SART1) results in inappropriate HIF-1 activation, and overproduction of downstream HIF-1 dependent chemokine, RANTES. HIF-1/RANTES upregulation accumulates TANs infiltration, which is associated with non-alcoholic steatohepatitis (NASH) driven HCC initiation and progression [53]. Moreover, recent studies suggested that TANs mediate the intratumoral infiltration of TAMs and regulatory T cells by overproducing some chemokines, such as CCL2 and CCL17, which then contributes to HCC progression, metastasis and resistance to sorafenib treatment [54]. A newly identified positive feedback loop implies that TANs induce HCC stem cell like characteristics via upregulating expression of miR-301b-3p in cancer cells, and maintain hyper-action in NF-kB signaling, lead to higher secretion level of C-X-C motif chemokine5 (CXC5) and in turn recruit more TANs infiltration [55]. In general, TANs are strongly connected with immunosuppression in HCC, but direct interactions between TANs and other components in HCC tissue and the exact underlying mechanisms behind this regulation in HCC are not yet clear.

**Tumor-infiltrating lymphocytes (TILs)**

A high density of tumor-infiltrating lymphocytes (TILs) was once thought to be the host’s immune reaction against cancer. Some early clinical data suggested postoperative HCC patients with high level lymphocytes infiltration, especially T cells, had reduced recurrence and better survival [56]. However, accumulating evidence suggests that the overall degree of TILs in HCC is not capable of mounting effective anti-tumor immunity to control tumor progression [57]. Intrahepatic immune response involves diverse lymphocyte populations, which contribute differently to HCC immune surveillance. The intratumoral balance of regulatory and cytotoxic T cells plays a key role in evaluating the immune state and progression of HCC [57, 58].

**Regulatory T cell (Treg)**

Regulatory T cells (Tregs) can be derived from peripheral blood T lymphocytes, resident T cells and other cellular sources. Its recruitment has been found to be induced by the CCR6 (CC chemokine receptor type 6)–CCL20 (CC motif chemokine 20) axis. Tregs activation is induced by T cell receptor (TCR) engagement concurrent with IL-10 and TGF-β signaling [59]. Apart from activation via pro-inflammatory signals, recent investigations elucidate that long noncoding RNAs (LncRNAs) may play pivotal roles in driving Tregs differentiation and implications during HCC progression [60]. Overexpressed Lnc-epidermal growth factor receptor (Lnc-EGFR) in Tregs binds to EGFR and prevents its ubiquitination by c-CBL, augmenting activation of its downstream AP-1/NF-AT1 axis in Tregs thus to promote immunosuppression in HCC [60]. Moreover, Amphiregulin (AREG), a multifunctional player, may enhance Tregs suppressive function via the EGFR motivation as well [61].

The frequencies of Tregs are associated with HCC invasiveness and have a crucial role in hampering the development of effective anti-tumor responses in HCC [57, 62]. Recent evidence indicates that CD4+CD25+ Tregs in HCC patients can trigger a compromised immune response through various mechanisms [63]. A typical subset, CD4+CD25+Foxp3+ Tregs, may impair CD8+ T cells killing capacity via inhibiting the release and production of granzyme A, B (GrA, B), and perforin [64], concurrently, they also selectively suppress certain molecules (such as TNF-α, IFN-γ) involved in CD8+ T cell activation [64, 65]. Additionally, high expression of IL-35 in HCC tissue has been implicated positively to correlate with another newly identified subtype, CD39+Foxp3+ Tregs infiltration [66], which serves as a better independent predictive indicator for recurrence in HCC patients after curative resection.

**CD8+ cytotoxic T lymphocytes (CTLs)**

The presence of CD8+ Cytotoxic T lymphocytes (CTLs) in HCC tissue is associated with improved survival. However, the efficacy of CTLs-mediated anti-tumor immune response is functionally limited through diverse mechanisms. Physical conditions (e.g. overload of lactic acid, low pH, hypoxia) [67], severe “metabolic competition” with tumor cells, a lack of CD4+ T cells help
(moreover, interact with Tregs and other suppressor cells) [64, 68], and high expression of a large amount of immunoregulatory molecules in T cells or HCC cells (e.g. IL-10, Fas/FasL, CXCL17, VEGF, indoleamine-2,3-dioxygenase and so on) [67, 69–71], may be responsible for restricted tumor-associated antigens (TAAs)-specific CD8+ T cell responses and poor IFN-γ production of CTLs [72, 73]. Apart from the classic immunosuppressive cells in TME, other components critically manipulate the functions of CTLs as well. Liver fibrosis, a prominent characteristic of HCC, impairs platelet-derived CD44 recognition by CD8+ T cells, reducing effector CD8+ T cells infiltration, and adhering to liver sinusoids to perform immunosurveillance [74]. Expression of Fas/FasL in CD8+ T cells positively correlates with HCC anti-tumor immunity [69]. Recent evidence indicates that tumor-derived vascular endothelial growth factor A (VEGF-A) and prostaglandin E2 (PGE2) cooperatively induce FasL expression in endothelial cells, which leads to excessive turnover of CD8+ T cells and reduce anti-tumor immune responses [71]. CD14+ dendritic cells (CD14+ DCs), a newly discovered immune regulator of HCC, has been suggested to suppress CTLs via IL-10 and indoleamine-2,3-dioxygenase (IDO) production, and the two cytokines play central roles in various physiological and pathological immune responses and inflammatory processes [75].

Notably, immune checkpoint signaling, which involves enhancement of numerous inhibitory co-stimulatory molecules (e.g. PD-1, LAG-3, CTLA-4, Tim-3, 2B4), has been demonstrated to dramatically induce CTLs exhaustion [80, 81]. These pro-inflammatory cytokines were associated with a low recurrence rate and a prolonged overall survival (OS) of HBV-related HCC patients [83]. In contrast, extended effect of AFP negatively affects long-term NK cell viability [82].

Other modulators in TME of HCC also exert multiple effects on NK activities (Fig. 2.). As mentioned above, MDSCs and TAMs infiltration inhibit autologous NK cell cytotoxicity and cytokine production, and the suppression is mainly dependent on NKP30 on NK cells [28]. Tregs compete with NK cells for IL-2 availability and impair NK responses via cytokines release, such as IL-8, TGF-81 and IL-10, which then down-regulates expression of NKR ligands on hepatic stellate cells (HSCs) and inhibits their recognition by NKG2D [84]. Hepatocellular carcinoma-associated fibroblasts (CAFs or TAFs), has been shown to induce MDSCs generation through the IL-6/STAT3 axis and stromal cell-derived factor (SDF)-1α secretion [18]. In addition to its direct influence on immunosuppressive TME, CAFs-derived IDO and PGE2 attenuate NK cells-mediated TNF-α and IFN-γ production, which may be associated with persistent fibrosis in HCC and tumor cell immune evasion [85, 86].

**Innate immune players and stromal components**

**Natural killer (NK) cells**

Natural killer (NK) cells constitute a large proportion of the innate immune system in the liver. As the first line of host defense against viral infections (e.g. HBV, HCV) and carcinogenesis, NK cells play a key role in maintaining the balance between immune defense and tolerance. Increasing evidence suggests that hypoxic stress in HCC tissue, switch of activating/inhibitory NK receptors (NKR)s and influences by immune regulatory components in TME, largely contribute to NK cells dysfunction, which significantly correlates with fatigue anti-tumor immunity and poor prognosis [78, 79].

α-Fetoprotein (AFP) overexpressed by HCC cells was demonstrated to indirectly impair interleukine-12 (IL-12) production from dendritic cells (DCs), which results in attenuated cytotoxic effector molecules release, decreased expression of natural killer group 2, member D (NKG2D), an activating receptor on NK cells, and subsequently inhibiting activation and ability of NK cells [80, 81]. A recent study also indicates AFP may exert dual effects on NK cells functions in a direct manner. Short-term exposure to AFP induces IL-2 hyperresponsive phenotype NK cells, accompanied with elevated secretion of IL-1β, IL-6 and TNF-α [82]. These pro-inflammatory cytokines were associated with a low recurrence rate and a prolonged overall survival (OS) of HBV-related HCC patients [83]. In contrast, extended effect of AFP negatively affects long-term NK cell viability [82].

Kupffer cells (KCs)

KCs have previously been demonstrated to constitute an important part in maintaining liver immune homeostasis. Some studies reported that IL-10-mediated suppression of KC-derived inflammatory TNF-α and NO production contribute to attenuation of hepatitis [87]. Although KCs were once regarded as a powerful line of defense against tumors in the liver, recently, KCs have commonly been explored as pro-carcinogenic stakeholders in the context of HCC, more underlying mechanisms about their immune regulator roles, and KCs-related innate or adaptive immune response have been gradually uncovered. Current investigations indicate that altered functions of KCs are mainly influenced by pro-inflammatory signals and other suppressive cells (e.g. MDSCs) [88]. Triggering receptors expressed on myeloid cells-1 (TREM-1) expressed by KCs, is a crucial factor in HCC initiation. New studies suggest that the potential ligand for TREM-1, high mobility group Box 1 (HMGB1) released by necrotic hepatocytes, is likely involved in activating KCs pro-inflammatory signaling.
and promoting HCC progression [89]. Autophagy-defective KCs, a novel non-parenchymal liver cellular degradation deficiency, has been shown to promote liver fibrosis, inflammation and hepatocarcinogenesis during the pre-neoplastic stage via enhancing the mitochondrial ROS/NF-κB/IL-1 pathway [90]. In addition, KCs-derived galectin-9, the natural ligand for the T cell immunoglobulin domain and mucin domain protein 3 (Tim-3), leads to expansion of CD4⁺ CD25⁺ FoxP3⁺ Tregs, contraction of CD4⁺ effector T cells, and apoptosis of CTLs in HCC [91]. Galectin-9 not only mediates T-cell senescence in HBV-associated HCC, significantly contributes to the inflammatory reactions and HCC immune escape [92], but notably also represents a potential biomarker of liver fibrosis and may emerge as a novel immunotherapeutic target for treating HCC and liver viral infections [92, 93].

**Dendritic cells (DCs) and DC-based vaccines**

Similar to NK cells, as another major player of innate immunity, DCs serve as professional antigen-presenting cells that are able to prime T-cells against tumor-associated antigens (TAAs) involved in HCC progression. Recently, DCs have been an area of high interest as novel vaccines based on DCs have been developed and widely used in treating solid tumors including prostate cancer, melanoma, renal cancer and HCC [94]. DCs engineered with tumor-associated antigens (TAAs), which have been clarified by numerous in vitro and in vivo studies, are regarded as promising vaccines in HCC immunotherapy. In addition, autologous DCs pulsed ex vivo with
the lysate of autologous tumor cells, HepG2 cells and telomerase peptides, have been evaluated in human clinical trials.

Recently, the Dendritic cell (DC)-derived exosomes (DEXs) and tumor cell–derived exosomes (TEXs), which elicit tumor regression in autochthonous HCC mouse models, form a new class of cell-free vaccines and extend options for HCC immunotherapeutic vaccines [95, 96] (Table 1).

**Representative immune inhibitory factors and modulators**

The abundance of pro-inflammatory chemokines, cytokines and immunosuppressive molecules, which orchestrates a strongly immunosuppressive tumor milieu, play critical roles in reshaping TME, mediating intercellular crosstalk, and exerting immune evasion-promoting effects of HCC. Some of their specific functions have been mentioned while discussing immune cells of HCC, here, we summarize the representative players that current studies mainly highlight (Table 2).

**Current immunotherapeutic strategies for HCC**

As an inflammation-associated cancer, HCC represents a promising target for immune based therapeutics. Clinically, the success of immune oncology in many types of cancer has encouraged implementation of immunotherapeutics in HCC. Recent studies have suggested that tumor antigen-specific immunotherapy and other approaches modulating immunogenicity have become attractive strategies for HCC treatment. Generally, these immunotherapeutic approaches for HCC could be mainly categorized into immune-checkpoint blockade (ICB), cell-based (mainly refers to DCs) /non-cell based vaccines, adoptive cell transfer (ACT), cytokine/antibody based immune regimens, and combination of immunotherapeutic agents with other drugs (Fig. 3). Here, we collect some representative data on preclinical and clinical trials on immune based strategies of HCC, and discuss our current knowledge on their action mechanisms, rationale and application prospects for HCC treatment in the foreseeable future.

**Immune checkpoint inhibitors**

Immune checkpoints are a specific sub-type of membrane-bound molecules that act as pivotal regulators of immune escape in cancers. The most studied immune checkpoints in HCC includes cytotoxic T lymphocyte protein 4 (CTLA-4), programmed cell death protein-1 and its ligand (PD-1, PD-L1), lymphocyte activation gene 3 protein (LAG-3) and mucin domain-containing molecule-3 (Tim-3).

**Programmed cell death protein-1 and its ligand (PD-1, PD-L1)**

PD-1, a regulator immunoglobulin expressed on activated CD4+, CD8+ T cells, B cells and NK cells, plays an important role in maintaining immune tolerance and repressing cytotoxicity of T lymphocytes [123]. Co-inhibitory signals in lymphocytes are mediated by binding of PD-1 to its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) [124]. In HCC, it’s clear that an increase in the number of both circulating and intratumoral PD-1+ CD8+ T cells predict high postoperative recurrences and poorer prognosis. It is also known that up-regulation of PD-L1 on HCC cells, which is induced by various cytokines, particularly IFN-γ, in turn contributes to impairing anti-tumor immunity and promotes CD8+ T cells apoptosis [110]. New in vitro and in vivo discoveries indicate that PD-1 overexpressed myeloid cells, such as DCs, suppress T cell responses in HCC. CD8+ T cells can be more potently activated to secrete IL-2 and IFN-γ via adoptive transfer of PD-1-deficient DCs [111].

Clinically, a representative phase 1/2 dose escalation and expansion trial on PD-1 immune checkpoint inhibitors Nivolumab (CheckMate 040 study) showed a promising role for immunotherapy in the treatment of advanced HCC, and relevant results were presented at the 2017 ASCO annual meeting [125]. In dose-escalation phase (enrolled number = 48), the objective response rate (ORR) was 15%, the disease control rate (DCR) was 58% and the median time to progression was 3.4 months. In dose-expansion phase (total number = 214; in 4 cohorts), generally, the ORR was reported as 20%, the DCR was 64%, the median time to progression was 4.1 months, and the 6-month and 9-month progression-free survival rates were 83 and 74% respectively. A subsequent CheckMate-040 based analysis compared the ORR and survival between intent-to-treat (ITT) overall population and Asian cohort. It suggested that Nivolumab showed similar mOS and manageable safety profile both in ITT population and Asian patients [126].

The efficacy of another anti-PD-1 monoclonal antibody, Pembrolizumab, was assessed in a phase II, open-label trial (KEYNOTE-224). In this study, Pembrolizumab was proven to be effective and well-tolerated in Sorafenib-experienced patients with advanced HCC, and PD-L1 expression level may act as a useful predictive bio-marker in selecting interested HCC patients. A total of 104 enrolled patients in this study represented 8-month median duration of response (mDOR), with median time to response of 2 months [127].

In addition, another phase 3 randomised clinical trial of nivolumab mono-therapy compared with sorafenib in the first-line setting is ongoing (NCT02576509). Moreover, combination therapies of anti-PD-L1
| Biological effects of DCs-based vaccines in HCC: representative in vitro and in vivo investigations |
|----------------------------------|---------------------------------|----------------------------------|----------------------------------|----------------------------------|
| **Agents** | **Descriptions** | **Trial category** | **Biological effects or clinical results** | **References** |
| AFP and interleukin 18 engineered DCs (AFP/IL-18-DCs) | DCs co-transduced with the AFP gene and IL-18 | In vitro studies | • Significantly increase the production of IFN-γ<br>• Promote CD4+ T cells proliferation; elevate CTLs activity against AFP-expressing HCC cells | [97] |
| DCs pulsed with NY-ESO-1 | DCs pulsed with the recombinant NY-ESO-1 protein | In vitro studies | • Be more effective in stimulating T cell proliferation compared with immature DCs | [98] |
| IL-12 engineered DCs (IL-12-DCs) | Endogenous IL-12-expression by adenoviral gene transfer effectively enhances immunostimulation of DC | Translational trials with murine models | • Induce a sufficient Th1 TME allowing the recruitment of T<sub>eff</sub> to enhance anti-tumor immunity<br>• Improve dendritic cells (DCs)-based immunotherapy of HCC | [99] |
| CD40 Ligand-Expressing DCs | Transduction of TAA-pulsed DCs with CD40L-encoding adenovirus (Ad-CD40L) | Translational trials with mice models | • Promote DC immunostimulation with up-regulation of CD80/CD86 and IL-12 expression<br>• Increase tumor infiltration with CD4<sup>+</sup>, CD8<sup>+</sup> T cells and NK cells<br>• Elevate IFN-γ release and CTLs cytotoxicity | [100] |
| TEXs pulsed DCs | Tumor cell derived exosomes (TEXs)-pulsed DCs | In vitro and in vivo orthotopic HCC mice models | • Increase numbers of T lymphocytes infiltration, elevate IFN-γ production; decrease IL-10, TGF-β in tumor sites<br>• Elicit a stronger immune response than cell lysates in vitro and in vivo | [95] |
| A new form vaccine: DCs-DEXs | Exosomes derived from AFP-expressing DCs | Translational investigation in mouse models | • A cell-free vaccine option for HCC immunotherapy<br>• Decrease Tregs infiltration, IL-10, TGF-β in tumor sites<br>• Reshape the TME in HCC | [96] |
| TAAs pulsed DCs vaccine | α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins pulsed DCs | A prospective phase I/II clinical study in 5 HCC patients | • Result: safe and well-tolerated<br>• Over 95% of DCs demonstrated highly expressed MHC class I (HLA-ABC), MHC class II (HLA-DR), and costimulatory molecules (CD86, CD80, and CD40)<br>• Induce Th1 immune responses with highly produced IL-12, IFN-γ<br>• Trigger stronger CTLs responses | [101] |
| TAAs pulsed DCs vaccine | α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins pulsed DCs | A prospective phase I/II clinical study in 12 HCC patients | • Result: safe and well-tolerated<br>• 1-, 2-, and 5-year cumulative RFS rates were improved | [102] |
| DCs pulsed with tumor cell lysate | Mature autologous DCs pulsed ex vivo with HepG2 lysate | A phase II clinical trial with 35 patients with advanced HCC | • Result: safe and well-tolerated<br>• MS: 168 days; 6-month survival rate: 33%; 1-year survival rate 11%<br>• Induce stronger T cell responses and IFN-γ release | [103] |
| DCs pulsed with tumor cell lysate | Mature autologous DCs pulsed ex vivo with HepG2 lysate | A clinical trial with 2 groups: Group1: 15 advanced HCC patients received DCs vaccination Group2: control group | • Result: safe and well-tolerated<br>• CD8<sup>+</sup> T cells and serum IFN-γ were elevated after DCs injection<br>• Partial radiological response: 13.3%; stable course: 60%; and 26.7% showed progressive disease and died at 4 months post-injection | [104] |
| DCs pulsed with AFP | AFP peptides pulsed onto autologous DCs | A phase VII clinical trial in which HLA-A*0201 patients with AFP-positive HCC, 10 patients received DCs vaccination | • 6 of 10 subjects increased IFN-γ producing AFP-specific T cell responses | [105] |

**Notes:** TAA tumor-associated antigens, MAGE-1 melanoma-associated antigen 1, GPC-3 glypican-3, IL-12 interleukin-12, AFP α-fetoprotein, TEXs tumor cell-derived exosomes, TGF-β transforming growth factor-β, TME tumor microenvironment, IFN-γ interferon-γ, DEXs dendritic cell-derived exosomes, CTLs cytotoxic T lymphocytes, Tregs regulatory T cells

antibody (Duvalumab) with anti-CTLA-4 antibody (Tremelimumab) for unresectable HCC are under study as well (NCT02519348).

Other reported combination immunotherapy studies are encouraging and really open new avenues for HCC treatment [128–130], however, additional strategies are
| Cytokines/signaling molecules | Category                          | Description                                                                                                                                                                                                 | References |
|-----------------------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| IL-1β                       | Pro-inflammatory cytokine         | • A favorable factor for prolonged OS of HBV-related HCC patients  
|                             |                                   | • TAMs-secreted IL-1β in HCC contributes to HIF-1α stability, IL-1β/HIF-1α induce EMT and metastasis of HCC                                         | [18] [37] |
| IL-12                       | Pro-inflammatory cytokine (anti-tumor immunity modulator) | • Promote cytotoxicity and IFN-γ production  
|                             |                                   | • Mediate CD4+ T helper cells transformation to Th1 phenotype, enhance cell based immunity  
|                             |                                   | • Up-regulate NKG2D related NKS anti-tumor immunity                                                                                               | [81–83]   |
| IL-8                        | Pro-inflammatory cytokine              | • Trigger potent pro-inflammatory signals in HCC, promote HCC immune evasion and metastasis  
|                             |                                   | • Enhance HCC-related fibrosis and Tregs enrichment in tumor tissue                                                                              | [33, 84, 106] |
| IL-10                       | Inhibitory cytokine that involves in both innate and adaptive immunity in HCC | • Tolerogenic DCs/ FcγRlow– B cells derived IL-10 induces hepatic tolerance by promoting T cell hypo-responsiveness  
|                             |                                   | • Suppress CD4+ T cells activity via CTLA-4-dependent manner  
|                             |                                   | • IL-10 production is associated with Foxp3+ Tregs accumulation in HCC  
|                             |                                   | • Accelerate HCC progression by mediating polarization of alternatively activated M2 macrophages                                                   | [38, 39, 75, 107, 108] |
| IL-6/STAT3                  | Pro-inflammatory/carcinogenesis signaling | • Mediate MDSCs activation then result in immunosuppression  
|                             |                                   | • Up-regulate IL-10, IDO expression; down-regulate IFN-γ, induce T cells dysfunction and apoptosis                                                   | [18, 109] |
| PD-1/PD-L1                  | Immune checkpoint molecules        | • Impairing anti-tumor immunity and promotes CD8+ T cells exhaustion and apoptosis  
|                             |                                   | • PD-1 over-expressed myeloid cells, such as DCs, suppress T cell responses in HCC                                                                  | [110, 111] |
| LAG3                        | Immune checkpoint molecule         | • Up-regulated on TAA-specific T cells  
|                             |                                   | • Significantly impairs CD4+ and CD8+ TILs functions in HCC                                                                                       | [112] |
| CTLA-4                      | Immune checkpoint molecule         | • Mediates immunosuppression by inducing Tregs activity and IL-10 productions in DCs  
|                             |                                   | • Suppresses the proliferation of T cells                                                                                                                                                                 | [73, 112] |
| Tim3/Galectin-9 pathway     | Immune checkpoint signaling        | • Negatively regulates Th1-mediated immune responses  
|                             |                                   | • Mediates CTLs dysfunction and immunosuppressive responses in HBV-associated HCC  
|                             |                                   | • Fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages                                                                                          | [27, 43, 76, 113] |
| VEGF, PDGF, HGF             | Major growth factors in TME of HCC | • Enhance interactions between TAFs/HSCs and HCC cells  
|                             |                                   | • Mediates recruitment of immune inhibitory cells  
|                             |                                   | • Mediates other pro-inflammatory signals in TME (e.g. IL-6/STAT3 axis)  
|                             |                                   | • Promotes angiogenesis and immune evasion                                                                                                                                                       | [18, 75] |
| IDO                         | Immunosuppressive modulator        | • High level IDO expression is associated with poor prognosis and high recurrence rate in HCC patients; a potential target for HCC immunotherapy  
|                             |                                   | • Enhance regulation of immune responses, such as T-cell proliferation impairment, promotion of Tregs expansion  
|                             |                                   | • IDO derived from HSCs and CAFs impair cytotoxicity and cytokine production of NK cells  
|                             |                                   | • CD14+CTLA-4+ regulatory DCs derived IDO suppress CTLs response; cause NKS dysfunction in HCC anti-tumor immunity                                                                                       | [75] [83, 85, 109, 114] |
| SDF-1α/CXCR4                | A multiple signaling that mediates HCC immune evasion, progression and metastasis | • Enhance interactions between TAFs/HSCs and HCC cells  
|                             |                                   | • Facilitate MDSCs recruitment and generation, then results in immune evasion  
|                             |                                   | • Contribute to HCC fibrosis and hypoxia  
|                             |                                   | • Synergize with other stroma-derived cytokines (such as HGF, VEGF, TGF-β and so on), promoting HCC growth, angiogenesis, metastasis                                                                 | [18, 115, 116] |
| CXCL17                      | 119-amino acid chemokine          | • An independent factor that correlates with HCC regulatory immune cells infiltration  
|                             |                                   | • Predict poor prognosis of HCC                                                                                                                                                                        | [70] |
| CCL2(also named MCP-1)      | Multifunctional factor            | • Multiple cellular resources, including HSCs, hepatocytes, macrophages and so on  
|                             |                                   | • CCL2/CCR2 promotes regulatory cytokines release, M2-macrophages accumulation and polarization                                                                                                           | [54, 117, 118] |
Cytotoxic T lymphocyte protein 4 (CTLA-4)

Cytotoxic T lymphocyte protein 4 (CTLA-4), an inhibitory co-receptor that is expressed by activated T cells and is constitutively present on Tregs, has great affinity for competing with CD28 by binding to its ligands, CD80 and CD86, on antigen presenting cells (APCs). CTLA-4 plays a critical part in controlling CD4+ T cells for competing with CD28 by binding to its ligands, and is constitutively present on Tregs, has great affinity for competing with CD28 by binding to its ligands, CD80 and CD86, on antigen presenting cells (APCs). CTLA-4 suppresses the proliferation of T cells that have undergone TAA recognition and differentiation [131]. Additionally, inside HCC tissues, CTLA-4 further mediates immunosuppression by inducing Tregs activity andIDO and IL-10 productions in DCs [75].

Many clinical trials of antibodies targeting CTLA-4 are ongoing. A pilot clinical investigation testing anti-tumor and anti-viral effects of Tremelimumab in patients with HCC and HCV infection showed strong signs of antitumour efficacy (NCT01008358). The treatment presents a reliable safety profile, as no immune-related adverse events occurred. The median time to progression (TTP) was 6.48 months, and median overall survival (OS) was 8.2 months. The partial response rate was observed as 17.6%, and had a remarkable disease control rate of 76.4%. Moreover, 36% of the patients with AFP levels > 100 ng/ml showed more than 50% drop after Tremelimumab therapies [132]. In another phase 1 clinical study that tests the safety and effectiveness of Tremelimumab with radiofrequency (RFA) (NCT01853618), the median TTP and median OS were respectively 7.4 months (95% CI 4.7 to 19.4 months) and 12.3 months (95% CI 9.3 to 15.4 months). The 6-week HCC biopsies showed a clear increase in CD8+ T cells infiltration demonstrating that the combination of Tremelimumab with RFA in advanced HCC is feasible and results in stronger anti-tumor immunity [133].

Mucin domain-containing molecule-3 (Tim-3) and lymphocyte activation gene 3 protein (LAG-3)

Mucin domain-containing molecule-3 (Tim-3) is a transmembrane protein that is expressed on IFN-γ-secreting Th1 cells, NK cells and CTLs [113]. Tim-3 interacts with its soluble ligand galectin-9, and then negatively regulates T cell responses [91]. The expression of Tim-3 is increased in T cells infiltrating in chronic HBV infection [134], and the Tim-3/galectin-9 pathway consistently predicts poor prognosis in patients with HBV-associated HCC [76].

Lymphocyte activation gene 3 protein (LAG-3), a member of the immunoglobulin super-family proteins, which often binds MHC class II molecules with high affinity to the α chain of the MHC class II molecules, is a suppressor molecule that downregulates T cell responses. LAG-3 interacts with its ligand MHC class II molecules, which are expressed on APCs, and this interaction is mediated by its C-C motif ligand (CCL26, CCL28) that activate STAT1/erk1/2 signaling. This interaction leads to upregulation of immune checkpoints (e.g. PD-L1, Tim3) and immune tolerogenic enzymes (e.g. IDO, ARG) that contribute to immune tolerance and angiogenesis.

Recruit CCR1+CD14+ monocytes infiltration, accelerate tumor proliferation and metastasis by activating STAT1/erk1/2 signaling. Upregulate immune checkpoints (e.g. PD-L1, Tim3) and immune tolerogenic enzymes (e.g. IDO, ARG) which often binds MHC class II molecules with high affinity to the α chain of the MHC class II molecules, is a suppressor molecule that downregulates T cell responses. LAG-3 interacts with its ligand MHC class II molecules, which are expressed on APCs, and this interaction is mediated by its C-C motif ligand (CCL26, CCL28) that activate STAT1/erk1/2 signaling. This interaction leads to upregulation of immune checkpoints (e.g. PD-L1, Tim3) and immune tolerogenic enzymes (e.g. IDO, ARG) that contribute to immune tolerance and angiogenesis.
affinity, represses the co-stimulatory functions of T cells [135]. Clinically, dual blockade of LAG-3 with anti-PD-1 therapy is being tested in a Phase I trial (NCT01968109) (Table 3).

The immunosuppressive roles of both Tim-3 and LAG-3 in chronic viral hepatitis and HCC have been uncovered recently. However, their clinical values need to be further elucidated.

Adoptive cell transfer (ACT) based therapy in HCC
Besides the immune-checkpoint blockade (ICB), other effective immunotherapeutic options for HCC are urgently needed. In recent years, the exploration and development of cell-based immunotherapies in treating solid tumors have received considerable attentions. Adoptive cell transfer (ACT) offers robust and more durable anti-tumor immunity in cancer treatment. Recent translational research and clinical cases reported the success of engineered autologous HBV-specific T cell receptor (TCR) redirected therapeutics in treating HBV-associated HCC [136, 137], which broadens the immunotherapeutic approaches and might be used to treat a wider population of patients [138]. Based on the cell types, ACT used in HCC pre-clinical/clinical researches can be mainly classified as: (1) cytokine-induced killer (CIK) cells treatment, and (2) genetically modified NK cells or T cells (CAR-T).

CIK cells are a mixture of T lymphocytes, which are ex vivo expanded in the presence of cytokines (such as IL-1, IL-2, IFN-γ), comprising activated NKT cells,
CD3+/CD56+ NK cells, and CD3+/CD56+ cytotoxic T cells [139]. CIK cells can be obtained in great numbers from peripheral blood mononuclear cells (PBMCs) and are very easily cultured. More importantly, it has been clarified that the absence of MHC restrictions favors CIK cells’ more potent anti-tumor efficacy compared with traditional CTLs [58, 139]. Previous studies suggested that CIK cells prevent HCC from progression, and effectively kill cancer stem cells (CSCs) mainly through NKG2d-ligands recognition [140]. A retrospective study demonstrated a significant correlation between high number of PD-1+ TILs and favorable outcome in

### Table 3: Representative ongoing immune checkpoint blockade (ICB) based immunotherapy clinical trials in HCC

| Regimen                                      | Disease                          | Mechanism of action                                    | Estimated/Actual enrollment | NCT number      |
|----------------------------------------------|----------------------------------|---------------------------------------------------------|----------------------------|-----------------|
| Anti-CTLA-4 antibody based monotherapy/combination therapy |                                |                                                         |                            |                 |
| Tremelimumab+TACE                            | Liver cancer                     | Anti-CTLA-4 antibody; chemoembolization                 | 61                          | NCT01853618     |
| Tremelimumab                                 | Advanced HCC                     | Anti-CTLA-4 antibody                                    | 20                          | NCT01008358     |
| Ipilimumab+Nivolumab/ Nivolumab alone following SBRT | Unresectable HCC                | Anti-PD-1 antibody, anti-CTLA-4 antibody               | 50                          | NCT03203304     |
| Anti-PD-1 antibody based monotherapy/combination therapy |                                |                                                         |                            |                 |
| Nivolumab+Y90 Radioembolization              | HCC                              | Liver-localized radioembolization, PD-1 blockade        | 40                          | NCT03033446     |
| Nivolumab+cabozantinib                       | Advanced HCC                     | Neoadjuvant therapy, PD-1 blockade                      | 15                          | NCT03299946     |
| Nivolumab+Pexa Vec                           | HCC                              | Oncolytic Immunotherapy, PD-1 blockade                  | 30                          | NCT03071094     |
| Nivolumab+Ipilimumab                         | HCC (Resectable and potentially resectable) | CTLA-4 blockade, PD-1 blockade                      | 45                          | NCT03222076     |
| Nivolumab following selective internal radiation therapy (SIRT) | HCC (unresectable)               | PD-1 blockade, radiation therapy                        | 40                          | NCT03381030     |
| Nivolumab following complete resection       | HCC                              | PD-1 blockade                                           | 530                         | NCT03383458     |
| Nivolumab+Galunisertib                       | NSCLC                            | TGF-β receptor 1 kinase inhibitor, PD-1 blockade        | 75                          | NCT02423343     |
| Nivolumab+Lenvatinib                         | HCC                              | TKI+ PD-1 blockade                                      | 26                          | NCT03418922     |
| Nivolumab+Y90                                | HCC                              | PD-1 blockade+Radioembolization                         | 35                          | NCT02837029     |
| Nivolumab+Sorafenib                          | HCC                              | PD-1 blockade+chemotherapy                              | 40                          | NCT03439891     |
| Nivolumab+CC-122 (Avadomide)                 | HCC (unresectable)               | PD-1 blockade+immunomodulator (targeting protein cereblon) | 50                          | NCT02859324     |
| Nivolumab+deb-TACE                           | Advanced HCC                     | PD-1 blockade+transarterial chemoembolization           | 14                          | NCT03143270     |
| Nivolumab+Mogamulizumab                      | HCC other solid tumors           | PD-1 blockade+anti-CCR4 antibody                        | 188                         | NCT02705105     |
| TATE followed by Nivolumab or Pembrolizumab  | HCC, mCRC                        | PD-1 blockade+TACE                                     | 40                          | NCT03259867     |
| Nivolumab                                    | Advanced HCC (with or without viral infections) | PD-1 blockade                                      | 262                         | NCT01658878     |
| Nivolumab (vs. Sorafenib)                    | Advanced HCC                     | PD-1 blockade                                          | 726                         | NCT02576509     |
| Anti-PD-L1 antibody based monotherapy/combined therapy |                                |                                                         |                            |                 |
| Durvalumab+tremelimumab                      | Unresectable HCC                 | Anti-PD-L1 antibody, anti-CTLA-4 antibody               | 440                         | NCT02519348     |
| Durvalumab monotherapy; Durvalumab+Tremelimumab vs. Sorafenib | Unresectable HCC                 | Anti-PD-L1 antibody, anti-CTLA-4 antibody               | 1200                        | NCT03298451     |
| Durvalumab+Guadecitabine (SGI-110)           | Liver cancer; pancreatic cancer; bile duct cancer; gallbladder cancer | Anti-PD-L1 antibody, small molecule DNA methyltransferase 1 (DNMT1) inhibitor | 90                          | NCT03257761     |
| Durvalumab+Tremelimumab+ablative therapies   | Advanced HCC and BTC             | Anti-PD-L1 antibody, anti-CTLA-4 antibody               | 90                          | NCT02821754     |
| Durvalumab+Ramucirumab (LY3009806)           | GEI adenocarcinoma; NSCLC; HCC   | Anti-PD-L1 antibody, anti-VEGFR2 antibody               | 114                         | NCT02572687     |
| Anti-LAG-3 antibody in combination with anti-PD-1 blockade |                                |                                                         |                            |                 |
| Relatlimab+Nivolumab                         | Different types of solid tumor (including HCC) | Anti-LAG-3 antibody,anti-PD-1 antibody               | 1000                        | NCT01968109     |

Notes: Y90 yttrium Y 90 glass microspheres, deb-TACE drug eluting bead transarterial chemoembolization, TATE transarterial tirapazamine embolization, mCRC metastatic colorectal cancer, BTC biliary tract carcinomas, GEI gastroesophageal junction, SIRT stereotactic body radiotherapy
CIK cells treated HCC group, which suggested that PD-1+ TILs may be utilized to predict the efficacy of CIK treatment in post-operative HCC patients [141]. A randomized, phase 3 clinical trial of the efficacy and safety of CIK cells treatment in 230 patients with HCC (NCT00699816) indicates that for post-curative treatment in HCC patients, adjuvant immunotherapy with CIK cells can prolong recurrence-free survival and OS (median RFS:44.0 months in treatment group, 30.0 months in the control group). Additionally, the proportion of patients with serious adverse events did not differ significantly between the treatment and control groups [142]. Several trials of CIK cells treatment in combination with other therapies, such as RFA, arterial chemoembolization and epitope-pulsed DCs, have been reported [143–145]. The evidence obtained from a growing body of literature confirms that CIK cells is a very promising adoptive immunotherapy that can be exploited for treatment and prevention of recurrence in HCC. However, a small fraction of patients undergoing standard therapies suffer from ‘immune fatigue’ status, and lack adequate leukocytes [139], a major obstacle for CIK cells treatment that needs to be overcome urgently. (Ongoing CIK-based clinical trials are available in Table 4.)

Another adoptive cell immunotherapy, which uses chimeric antigen receptor-modified T cells (CAR-T) or genetically modified NK cells, has been shown to be a promising strategy for the treatment of HCC. CAR-T can specifically recognize tumor-associated antigens and effectively eliminate tumor cells in a non-MHC restricted manner. Furthermore, additional genes could be used to enable resistance to immune suppression [146]. Successful use of CAR-T cells in treating haematological malignancies includes ACT using CD19-specific CAR-T cells and the third-generation of CD20-specific CAR with CD28 and 4-1BB co-stimulatory domains. CAR-T cell treatment is well tolerated and can induce great responses detected, partially due to the limited number of antigens used or deficient CD4+ helper T cell support [157, 160, 161]. A vaccine with a single 16 amino acids sequence, hTERT-derived peptide (GV1001), and binds multiple HLA class II molecules, results in little clinical activity and no detected measurable anti-tumor responses and are associated with prolonged OS of HCC patients [156, 162].

Non-cell based vaccines and oncolytic viruses based immunotherapy in HCC

With the identification of a growing number of tumor-associated antigens (TAAs), and as a result, vaccines targeting HCC TAAs have been investigated and developed. A number of tumor antigens, such as human alpha-fetoprotein (AFP), GPC-3 and telomerase-reverse transcriptase (hTERT) have been identified as vaccine-based immunotherapeutic targets for HCC [154]. Another gene-modified NKS candidate, human interleukin-15 (hIL-15) gene-modified NKL cells (NKL-IL15), has been demonstrated to express high levels of cytolyis-related molecules (TNF-α, IFN-γ, NKP80 and so forth), which induces higher NKG2D ligand expression on target cells and results in increased susceptibility of HCC to NKS-mediated cytolysis [153].

Collectively, genetically modified NKs and CAR-T cells based treatment provide new avenues for immunotherapies against HCC. Nevertheless, before being widely used as therapeutics in the clinic, their clinical efficacy and on-target-off tumor toxicity still require further assessments in more randomized trials.

### Non-cell based vaccines and oncolytic viruses based immunotherapy in HCC

With the identification of a growing number of tumor-associated antigens (TAAs), and as a result, vaccines targeting HCC TAAs have been investigated and developed. A number of tumor antigens, such as human alpha-fetoprotein (AFP), GPC-3 and telomerase-reverse transcriptase (hTERT) have been identified as vaccine-based immunotherapeutic targets for HCC [154].

Table 5. Although increased efforts are being made to advance TAAs-based vaccines, the early clinical trials witnessed a mixed history of success and failure [155–157, 160]. The first HCC AFP-vaccine clinical trial was completed with only transient immunological responses detected, partially due to the limited number of antigens used or deficient CD4+ helper T cell support [157, 160, 161]. A vaccine with a single 16 amino acids sequence, hTERT-derived peptide (GV1001), and binds multiple HLA class II molecules, results in little clinical activity and no detected absolute antigen-specific CTLs responses [155]. On the other hand, partial clinical data on GPC-3 based vaccines demonstrated that the vaccine could induce measurable anti-tumor responses and are associated with prolonged OS of HCC patients [156, 162].

Apart from these classical TAAs, another attractive target is cancer-testis antigens (CTAs), which are considered to be novel targets for HCC immunotherapy due to the restricted expression patterns in a variety of tumors and normal tissues [163]. NY-ESO-1, also known as CTAG1, is one of the most immunogenic CTAs. A number of previous studies reported that NY-ESO-1 is
| Regimen                          | Population                                                                 | Design                                                                 | Estimated/Actual enrollment | NCT number        |
|---------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------------|------------------|
| CIKs mono-therapy for HCC       | • Hepatocellular carcinoma                                                | • Phase 3 clinical trial                                               | 200                       | NCT00769106      |
|                                 | • Renal cell carcinoma                                                    | • CIK treatments within 3 months after liver resection                 |                           |                  |
|                                 | • Lung cancer                                                             | • CIK treatments following radical resection                           |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Hepatocellular carcinoma                                                | • Phase 3 clinical trial                                               | 200                       | NCT01749865      |
|                                 |                                                                            | • CIK treatments following radical resection                           |                           |                  |
|                                 | • Renal cell carcinoma                                                    | • CIK treatments following radical resection                           |                           |                  |
|                                 | • Lung cancer                                                             |                                                                        |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Hepatocellular carcinoma                                                | • Phase 2 clinical trial                                               | 100                       | NCT01821482      |
|                                 |                                                                            | • Dendritic and CIKs used to treat HCC patients who got CR or PR after complete resection/ TACE |                           |                  |
| CIKs in combination with other therapies for HCC | • Hepatocellular carcinoma                                                | • Phase 2 clinical trial                                               | 50                        | NCT02886897      |
| CIKs+ anti PD-1 antibodies      | • Renal cell carcinoma                                                    | • Phase 2 clinical trial                                               |                           |                  |
|                                 | • Bladder cancer                                                          | • Combination therapy                                                 |                           |                  |
|                                 | • Colorectal cancer                                                       |                                                                        |                           |                  |
|                                 | • Non-small-cell lung cancer                                              |                                                                        |                           |                  |
|                                 | • Breast cancer                                                           |                                                                        |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Hepatocellular carcinoma                                                | • Phase 3 clinical trial                                               | 60                        | NCT02487017      |
|                                 | • Digestive system neoplasms                                              | • Combination therapy                                                 |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Hepatocellular carcinoma                                                | • Phase 3 clinical trial                                               | 210                       | NCT02678013      |
|                                 |                                                                            | • RFA + Highly-purified CTL vs. RFA Alone for Recurrent HCC after partial hepatectomy |                           |                  |
| CAR-T trials for HCC treatment  | • Hepatocellular carcinoma                                                | • Phase 1/2 clinical trial                                             | 20                        | NCT03084380      |
| Anti-GPC3 CAR-T                 | (GPC3 + advanced HCC)                                                     |                                                                        |                           |                  |
|                                 |                                                                            | • GPC3-CAR-Treatment mediated by the method of transcatheter arterial infusion (TAI) |                           |                  |
| Anti-GPC3 CAR-T                 | (GPC3 + advanced HCC)                                                     | • Phase 1/2 clinical trial                                             | 60                        | NCT02723942      |
|                                 |                                                                            | • The second generation CAR-T treatment                                |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • AFP expressing hepatocellular carcinoma                                 | • Phase 1 clinical trial                                               | 18                        | NCT03349255      |
|                                 |                                                                            | • The second generation CAR-T treatment                                |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Advanced hepatocellular carcinoma                                      | • Phase 1 clinical trial                                               | 13                        | NCT02395250      |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Advanced hepatocellular carcinoma                                      | • Phase 1 clinical trial                                               | 30                        | NCT03198546      |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Advanced hepatocellular carcinoma                                      | • Phase 1/2 clinical trial                                             | 30                        | NCT02715362      |
| TAI-GPC3-CAR-T                  | • Hepatocellular carcinoma                                                | • Phase 1/2 clinical trial                                             |                           |                  |
|                                 |                                                                            | • GPC3-CAR-Treatment mediated by the method of transcatheter arterial infusion (TAI) |                           |                  |
|                                 | • Hepatocellular carcinoma                                                | • Phase 1/2 clinical trial                                             |                           |                  |
|                                 |                                                                            | • GPC3-CAR-Treatment by intratumor injection                           | 10                        | NCT03130712      |
|                                 | • Advanced hepatocellular carcinoma                                      | • Phase 1/2 clinical trial                                             |                           |                  |
|                                 | • Advanced hepatocellular carcinoma                                      | • Phase 1/2 clinical trial                                             |                           |                  |
|                                 | • Hepatocellular carcinoma                                                | • Phase 1/2 clinical trial                                             |                           |                  |
|                                 | • Non-small cell lung cancer                                              | • Patients with MUC1+ advanced refractory solid tumor                  | 20                        | NCT02587689      |
|                                 | • Pancreatic carcinoma                                                    |                                                                        |                           |                  |
|                                 | • Triple-negative invasive breast carcinoma                               |                                                                        |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Relapsed or refractory hepatocellular carcinoma                         | • A single arm, open-label pilot study                                 | 20                        | NCT03146234      |
|                                 | • Hepatocellular carcinoma                                                | • GPC3+ hepatocellular carcinoma                                      |                           |                  |
|                                 |                                                                            | • GPC3-CAR-Treatment by intratumor injection                           |                           |                  |
|                                 | • Colon cancer                                                            | • Phase 1/2 clinical trial                                             | 60                        | NCT03013712      |
|                                 | • Esophageal carcinoma                                                    | • Targeting patients with EpCAM+ cancer                              |                           |                  |
|                                 | • Pancreatic cancer                                                       |                                                                        |                           |                  |
|                                 | • Prostate cancer                                                         |                                                                        |                           |                  |
|                                 | • Gastric cancer                                                          |                                                                        |                           |                  |
|                                 | • Hepatic carcinoma                                                       |                                                                        |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 | • Hepatocellular carcinoma                                                | • Phase 1/2 clinical trial                                             | 20                        | NCT02959151      |
|                                 | • Pancreatic cancer                                                       | • CAR-T targets: GPC3 for hepatocellular carcinoma                     |                           |                  |
|                                 | • Colorectal cancer                                                       | • Mesothelin for pancreatic cancer                                    |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |
|                                 |                                                                            |                                                                        |                           |                  |

Table 4 Clinical trials based on CIKs and genetically modified T cells under study for the treatment of HCC
highly expressed in many types of solid tumors, and a number of vaccine strategies targeting NY-ESO-1 are being developed [164–166]. In vitro investigations suggested that NY-ESO-1 expression is associated with poor tumor outcomes, and DCs loaded with NY-ESO-1 peptide can stimulate specific T cell responses against HCC cells [98, 167]. This implies that NY-ESO-1 has potential to be a valuable target molecule for immunotherapy against HCC. Clinically, vaccines targeting NY-ESO-1 expressing solid tumors (including HCC) are ongoing (NCT01522820).

Current studies demonstrate that DNA encoding epitope-optimized murine AFP and lentivector-mediated genetic immunization could induce potent AFP-specific CD8+ responses to generate a significant anti-tumor effect in autochthonous HCC model [168]. This may provide additional technology and new perspectives to further maximize the vaccines used in HCC therapy.

Oncolytic viruses (OVs) selectively replicate in tumor cells, damaging them, and subsequently spreading the virus in tumor tissue, while not harming normal cells. This characteristic endows OVs an effective platform for cancer immunotherapy [169]. Pre-clinical and clinical research highlights natural and genetically modified viruses, which are armed with immunomodulatory transgenes, that not only induce potent in situ antitumor immunity through mediating immunogenic cell death (ICD) and the inflammatory cascade, but also serve as vectors expressing therapeutic genes to improve cancer treatment [170, 171].

As for OVs used in HCC immunotherapy, previous in vitro and xenograft mice model studies indicated that a broad variety of therapeutic genes recombinant oncolytic adeno-associated viruses (AAVs) can exert a strong cytopathic effect on HCC cells (Fig. 4.). A tumor-selective replicating adenovirus expressing IFN-β, and ZD55-IFN-β, shows an elevated level of IFN-β expression, and 100-fold higher anti-tumor cytotoxicity than replicative adenovirus ONXY-015 [172]. The application of another recombinant AAVs model, AAV vectors containing human telomerase reverse transcriptase (hTERT) and tumor necrosis factor alpha related apoptosis inducing ligand (TRAIL) gene, namely AAV-hTERT/TRAIL, targets telomerase activity in HCC cells, and exhibits specific cytotoxicity and apoptosis to suppress the growth of HCC xenograft tumors [173]. An oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor (GM-CSF), Ad5-D24-GMCSF, induces tumor-specific and virus-specific immunity both in the syngeneic hamster model and patients. This suggests that oncolytic virus-mediated antitumor immunity may be a promising immunotherapeutic candidate for further clinical testing in HCC treatment [174].

In early clinical studies, oncolytic poxvirus JX-594 (also known as PexaVec), showed robust virus replication-dependent oncolysis, well-tolerated character, anti-vascular effects and anti-tumor immunity in HCC and other solid tumors [158, 175, 176]. (NCT00629759) (Table 5.) Another randomized trial in advanced HCC demonstrated oncolytic and immunotherapy mechanisms of action (MOA), tumor responses and dose-related survival (high-dose JX-594 was associated with longer OS) in individuals with HCC [159] (NCT00554372).

In general, OVs is a potent therapeutic agent for cancer treatment, and it’s promising to extend immunotherapeutic options for HCC. Importantly, dosing regimens of OVs must be better defined for its clinical use, and in this regard, further results from clinical trials are awaited.

**Conclusions**

HCC is characterized by immune tolerance and comprises numerous infiltrated immune cells, a great number of suppressive molecules, complex pro-inflammatory/immunoregulatory signaling and intricate interactions between different components. The picture of immune microenvironment in HCC plays a key role in HCC progression and recurrence. Apparently, interactions of HCC tumor cells and various immune components in TME are really complicated and multifaceted, finally determining the plasticity and heterogeneity of its both innate and adaptive immune responses. Transcriptional and epigenetical alterations [177], metabolic reprogramming [178] and lack of co-stimulatory signals partially contribute to exhausted phenotype of TILs. Moreover, importantly, the benefit of current predictive biomarkers (e.g. PD-L1 expression level and tumor mutation burden (TMB)) in HCC patients receiving ICBs are still limited. Despite some impressive basic and translational discoveries, more details about
underlying cellular or molecular mechanisms of immune evasion in HCC need to be further clarified. It’s clear that a better understanding of HCC immune landscape and will provide new breakthroughs in its clinical treatment.

Recently, immunotherapy brings great promises and new opportunities for HCC therapeutics. Its success has been evidenced by extensive studies. However, a subset of patients with HCC has little positive clinical responses to this treatment. In addition to the current combination regimens of ICBs with TKIs, or individualized cell therapeutic approaches, more effective ways to reinvigorate anti-tumor responses are urgently warranted. In this regard, combination of PD-1/PD-L1 monoclonal antibody

| Trial (the 1st author/responsible party) | Agent | Design | Population | Status/Relevant results | Registration no.& Reference order |
|----------------------------------------|-------|--------|------------|--------------------------|---------------------------------|
| Non-cell based vaccines                |       |        |            |                          |                                 |
| Greten et al. (2010)                   | GV1001: a telomerase derived peptide vaccine | A phase 2 open-label trial; 4-week injections with GM-CSF + GV1001 vaccinations | 40 patients with advanced HCC | Status: terminated Results: no relevant toxicity, median OS: 11.5 months, median PFS: 57 days, median TTP: 57 days, TTSP: 11.7 months | [155] NCT00444782 |
| SillaJen, Inc. (2016)                  |       |        |            |                          |                                 |
| Butterfield et al. (2013)              |AFP peptide vaccine | A pilot Phase 1 clinical trial | 6 patients with HCC | Status: terminated Results: all of the patients generated T-cell responses to most or all of the peptides as measured by direct IFN-γ ELISPOT and MHC class I tetramer assays | [157] |
| Immunitor LLC et al. (2018)            | An oral therapeutic vaccine: hepatitis B virus (HepV)-Vacc | A phase 3, randomized, placebo-controlled, double-blind trial | Estimated enrollment 120 patients with advanced HCC | Status: recruiting Results: none | NCT02232490 |
| Roswell Park Cancer Institute (2016)  | Vaccine therapy in treating NY-ESO-1 expressing solid tumors | A phase 1 clinical trial determines the safety of DC205-NY-ESO-1 vaccine | 18 patients with NY-ESO-1 solid tumors, including HCC | Status: completed Results: none | NCT01522820 |
| Butterfield et al. (2013)              |AFP+ GM-CSF Plasmid Prime and AFP Adenoviral vector Boost | A phase 1/2 trial Testing immunization with AFP + GM-CSF plasmid prime and AFP adenoviral vector | Actual enrollment: 2 patients with HCC | Status: terminated (Poor accrual and limited target patient population for future accrual, did not complete the Phase 1 portion of the trial.) | NCT00669136 |
| Oncolytic virus (OVs) based immunotherapy |       |        |            |                          |                                 |
| Byeong et al. (2008)                   | JX-594 | A phase 1 clinical trial, assessment of intratumoral injection of JX-594 into primary or metastatic liver tumors | 14 patients with primary or metastatic liver tumors | Status: terminated Results: well-tolerated MTD was determined as 1 × 10⁹ pfu; 10 patients were radiographically evaluable for objective responses; responses in 3 HCC patients; 3 serum tumor markers PR (250% decrease); 1 response according to PET | (NCT00629759) |
| Jeong Heo et al. (2013)                | JX-594 | A Prospective, randomized clinical trial with high or low dose JX-594 | 30 patients with unresectable liver tumors | Status: terminated Results: 11/16 patients showed cytotoxicity against HCC; 31% anorexia in high dose group RR: 4 PR, 10 SD by RECIST | (NCT00554372) |
| Jennerex Biotherapeutics (2008-2011)   | JX-594 (Pexa-Vec) | A phase 2b randomized trial | 129 patients with advanced HCC who have failed sorafenib | Status: completed Results: none (No results posted on ClinicalTrials.gov) | NCT01387555 |
| SillaJen, Inc. (2015)                  | Vaccinia virus based immunotherapy (Pexa-Vec) + Sorafenib | A multi-center, randomized, open-label, Phase 3 trial; Comparing Vaccinia Virus based Immunotherapy Plus Sorafenib vs Sorafenib alone | 600 patients with advanced HCC | Status: recruiting Results: none | NCT02562755 |

Notes: HCC hepatocellular carcinoma, P primary endpoint, S secondary endpoint, OS overall survival, TTP time to progression, TTSP time to symptomatic progression, SD stable disease, RR response rate, JX-594 aoncolytic pox virus carrying human GM-CSF genes, MTD maximum-tolerated dose, RECIST response evaluation criteria in solid tumors, PR partial response
and targeting co-stimulatory receptors (such as 4-1BB, OX40, CD27) with agonistic antibodies seems to be a potential therapeutic option for HCC, which may enhance and reverse functions of exhausted CD8⁺ TILs [179]. Additionally, strategies to target altered metabolic characteristics (e.g. the Warburg effect, abnormal glutamine metabolism, and urea cycle deficiency (UCD)) or interfere with the “key point molecules” (e.g. Arginase and indoleamine 2,3-dioxygenase (IDO)) that both influence metabolic reprogramming and T cell exhaustion may be a promising exploration clinically [180]. Moreover, some emerging pre-clinical investigations indicate the developing novel therapeutic approaches like epigenetic therapy using histone deacetylase inhibitors (HDACi) combined with CAR-T treatment are helpful for identification of more precise biomarkers and opening new avenues of HCC immunotherapy.

In general, immunotherapy is becoming one of the most promising approaches for HCC treatment, and it is likely to be more powerful in the foreseeable future.

**Abbreviations**

ACT: Adoptive cell transfer; AFP: A-fetoprotein; APCs: Antigen presenting cells; CAF: Cancer associated fibroblast; CAR-T: Chimeric antigen receptor-modified T cells; CCL2: Chemokine (C-C motif) ligand 2; CR: Cytokine-induced killer; CSCs: Cancer stem cells; CTA: Cancer-testis antigens; CTLA-4: Cytotoxic T lymphocyte protein 4; CTLs: Cytotoxic T lymphocytes; CXCL17: Chemokine (C-X-C motif) ligand 17; CXCR4: Chemokine (C-X-C motif) receptor 4; DCs: Dendritic cells; DEXs: Dendritic cell-derived exosomes; GPC-3: Glypican-3; HCC: Hepatocellular carcinoma; HGF: Hepatocyte growth factor; HSCs: Hepatic stellate cells; hTERT: Human telomerase-reverse transcriptase; ICB: Immune-checkpoint blockade; IDO: Indoleamine-2,3-dioxygenase; IFN-γ: Interferon-γ; IL-: Interleukin-; KC: Kupffer cell; LAG-3: Lymphocyte activation gene 3; MAGE-1: Melanoma-associated antigen 1; MCP-1: Monocyte chemotactic protein 1; MDSCs: Myeloid-derived suppressor cells; MTD: Maximum-tolerated dose; NK cell: Natural killer cell; OS: Overall survival; OVs: Oncolytic viruses; P: Primary endpoint; PD-1: Programmed cell death protein 1; PDGF: Platelet-derived growth factor; PD-L1: Programmed cell death protein ligand 1; PR: Partial response; RECIST: Response evaluation criteria in solid tumors; RR: Response rate; S: Secondary endpoint; SD: Stable disease; SDF-1α: Stromal cell derived factor 1α; TAA: Tumor-associated antigens; TAMs: Tumor-associated macrophages; TANs: Tumor associated neutrophils; TEMs: Tumor cell-derived macrophages; TGF-β: Transforming growth factor-β; Tim-3: Mucin domain-containing
molecule-3; TME: Tumor microenvironment; Tregs: Regulatory T cells; TTP: Time to progression; TSP: Time to symptomatic progression; VEGF: Vascular endothelial growth factor

Acknowledgements
Not applicable.

Authors’ contributions
YF, SL, SZ and HS designed and drafted the manuscript; YF, SZ and HS wrote figure legends and revised the article; SL drew the figures. All authors read and approved the final manuscript.

Funding
This study was supported by grants from the National Natural Science Foundation of China (No. 81172470, 81070362, 81372629 & 81772627), and two key projects from the Nature Science Foundation of Hunan Province (No. 2015JC3021 & No. 2016JC037).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China. 2National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China. 3Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.

Received: 30 May 2019 Accepted: 27 August 2019

Published online: 09 September 2019

References
1. Thirme R, et al. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology. 2008;48(6):1821–33.
2. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223–8.
3. Rimassa L, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20–8.
4. Aridet MA, et al. Inhibition of cyclin-dependent kinase 5: a strategy to improve Sorafenib response in hepatocellular carcinoma therapy. Hepatology. 2019;69(1):576–93.
5. Bolland J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, delays tumor growth in preclinical models of hepatocellular carcinoma. Gut. 2017;66(7):1286–96.
6. Ehrlich SM, et al. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma—a novel therapeutic approach. J Hepatol. 2015;63(1):102–13.
7. Joshi JJ, et al. H38-6527 is a potent and selective inhibitor of FGF4 in FGF19-driven hepatocellular carcinoma. Cancer Res. 2017;77(24):6999–7013.
8. Lang LT, Teng Y. Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cells. 2019;8(1). Published online 2019 Jan 9. https://doi.org/10.3390/cells8010031.
9. Shihomi A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:76–88.
10. Hato T, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014;60(5):1776–82.
11. Zhang HH, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat. 2010;17(Suppl 1):34–43.
12. Chew V, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114(29):E5900–9.
13. Wu Y, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 2013;57(3):1107–16.
14. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.
15. Kapanadze T, et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol. 2013;59(5):1007–13.
16. Mok MT, et al. CCR4 is a novel signalling hub exploitable in cancer immunotherapy. Pharmacol Ther. 2018;186:138–51.
17. Zhou J, et al. Hepatoma-intrinsic CCR4 inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018;67(5):931–44. https://doi.org/10.1136/gutjnl-2017-314032.
18. Deng Y, et al. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. Oncogene. 2017;36(8):1000–101.
19. Chiu DK, et al. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology. 2016;64(3):797–813.
20. Chiu DK, et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017;8(1):517.
21. Nan J, et al. Endoplasmic reticulum stress induced LOX-1(+)/CD154(+) polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma. Immunology. 2018;154(1):144–55. https://doi.org/10.1111/imn.12876.
22. Kondo Y, Shimosegawa T. Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs. Int J Mol Sci. 2015;16(2):3072–2.
23. Liu M, et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2019. https://doi.org/10.1136/gutjnl-2018-317257.
24. Hoescht B, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234–43.
25. Sivastava MK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cytokine and cytokine. Cancer Res. 2010;70(1):68–77.
26. Zhang H, et al. Critical role of myeloid-derived suppressor cells in tumor-induced liver immune suppression through inhibition of NK cell function. Front Immunol. 2017;8:129.
27. Daradallion V, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol. 2010;185(3):1383–92.
28. Hoescht B, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKP30 receptor. Hepatology. 2009;50(3):799–807.
29. Wu CJ, et al. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. Oncology. 2018;70(6):1477459.
30. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2013;141(1):39–51.
31. Movahedi K, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(15):678–87.
32. Hata T, et al. Immune checkpoint blockade efficacy. Gut. 2018;67(5):931–44. https://doi.org/10.1136/gutjnl-2017-314032.
33. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:76–88.
34. Wang TT, et al. CTGF secreted by mesenchymal-like hepatocellular carcinoma cells plays a role in the polarization of macrophages in hepatocellular carcinoma progression. Biomed Pharmacother. 2017;95:111–9.
35. Capece D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204.
36. Zhu Y, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitis
hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68(9):1653-66. https://doi.org/10.1136/gutjnl-2019-318419.

37. Zhang J, et al. HIF-1alpha/IL-1beta signaling enhances hepatoma epithelial-mesenchymal transition via macrophages in a hypoxic-inflammatory microenvironment. Hepatology. 2018;67(5):1872-89. https://doi.org/10.1002/hep.29681.

38. Zhou J, et al. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009;125(7):1640-8.

39. Sharma S, et al. CD4+CD25+CD127(bw) regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma. Front Immunol. 2015;6:49.

40. Kuang DM, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010;51(1):154–64.

41. Rani B, et al. Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2014;20(15):4128–40.

42. Lanaya H, et al. EGF-R has a tumor-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16(10):972–7.

43. Yan W, et al. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut. 2015;64(10):1593–604.

44. Hansen AL, et al. High level of PD-L1 expression is associated with shorter overall survival in hepatocellular carcinoma patients. Cancer. 2016;122(28):4469–78.

45. Muhanna N, et al. Amelioration of hepatic fibrosis by NK cell activation. Gut. 2015;64(10):1586–93.

46. Andzinski L, et al. Type I IFNs induce anti-tumor polarization of tumor-associated neutrophils. J Cancer Res. 2016;7(6):364–72.

47. Ameratunga M, et al. Neutrophil-lymphocyte ratio kinetics in patients with chronic HBV infection and hepatocellular carcinoma. J Hepatol. 2012;56(4):767–75.

48. Jeyakumar G, et al. Neutrophil lymphocyte ratio and duration of prior anti-HBV therapy correlate with survival after hepatectomy for hepatocellular carcinoma. Hepatol Int. 2014;8(3):216–22.

49. Nicolas-Avila JA, Adrover JM, Hidalgo A. Neutrophils in homeostasis, immunity, and Cancer. Immunity. 2017;46(1):15–28.

50. Kalathil S, et al. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73(8):4234–44.

51. Yuan CH, et al. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells. Oncotarget. 2015;6(31):32138–53.

52. Fu J, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132(7):2328–39.

53. Yuan CH, et al. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells. Oncotarget. 2015;6(31):32138–53.

54. Kuang DM, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma enhance immune surveillance. Cancer Res. 2016;76(4):1818–30.

55. Yu et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114(7):767–76.

56. Ye LY, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016;76(4):1818–30.

57. Kuang DM, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(4):1327–37.

58. Guo CL, et al. Expression of Fas/FasL in CD8+ T and CD8+ Foxp3+ Tregs cells—relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2014;15(6):2613–8.

59. Li J, et al. OX40L expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. PLOS One. 2014;9(10):e101004.

60. Motz GT, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–15.

61. Moreno-Cubero E, Larribia JR. Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol. 2016;22(28):689–93.

62. Rickert T, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59(4):1415–26.

63. Guidotti LG, et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell. 2015;161(1):486–500.

64. Han Y, et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology. 2014;59(2):567–79.

65. Li H, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56(4):1342–51.

66. Woo SR, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–27.

67. Kamimura H, et al. Reduced NKGD2 ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol. 2012;56(2):381–8.

68. Hasegawa K, et al. NK cell dysfunction by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

69. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

70. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

71. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

72. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

73. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

74. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

75. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

76. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

77. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

78. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

79. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.

80. Zhang C, et al. Interleukin-12 improves cytotoxicity of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165(2):211–9.
88. Lacotte S, et al. Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma. Oncoimmunology. 2016; 5(11):e1234565.

89. Wu J, et al. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012;72(16):3977–84.

90. Sun K, et al. Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mTORC-NF-kappaB-IL alpha/beta-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis. Cancer Lett. 2017;388:198–207.

91. Mengshol JA, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010(5):e9504.

92. Kim HY, Park JW. Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. Ther Adv Gastroenterol. 2017;10(1):805–14.

93. Fujita K, et al. Correlation between serum galectin-9 levels and liver fibrosis. J Gastroenterol Hepatol. 2018;33(2):492–9.

94. Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol. 2014;27:32–32.

95. Lu Z, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67(3):47–55.

96. Shi F, et al. Diffential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014;59(4):1435–47.

97. Sun GY, et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics. 2018;8(4):894–905.

98. Liu X, et al. Targeting of tumour-infiltrating macrophages via CCL2/C-CR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66(1):157–67.

99. Baeck C, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2012;61(3):416–26.

100. Lu LZ, et al. CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma. Hepatology. 2019;69(1):143–59.

101. Wei SC, et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017;170(6):1120–33 e17.

102. Lackman Y, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–8.

103. El AM, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.

104. Yau T, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib–experienced Asian cohort analysis. 2019;71(3):543-52. https://doi.org/10.1016/j.annonc.2019.05.014.

105. Zhu AX, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet. 2018;391(10110):940–52.

106. Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2018;283(2):110–20.

107. Mocan T, et al. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol. 2019;21(6):702–12.

108. Harding JJ. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncol. 2018;14(22):2293–302.

109. Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology. 2017;92(Suppl 1):50–62.

110. Sangro B, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet. 2018;391(10110):940–52.

111. Fang S, et al. Expression and prognosis role of indoleamine 2,3-dioxygenase (IDO) in hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2018;33(2):492–502.

112. Schmidt TL, Negrin RS, Contag CH. A killer choice for cancer immunotherapy. Immunol Res. 2014;58(2–3):300–312.
140. Rong XX, et al. Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKGD2-like ligands recognition. Oncoimmunology. 2016;5(3):e1086060.

141. Chang B, et al. High number of PD-1 positive intratumoral lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients. Liver Int. 2018;38(8):1449–58.

142. Lee JH, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148(7):1383–91.e6.

143. Huang ZM, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother. 2013;36(5):287–93.

144. Qu Y, et al. Hepatocarcinoma-specific immunotherapy with synthesized alpha1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J Gastroenterol. 2011;17(48):5260–6.

145. Pan K, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20(13):4305–11.

146. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013;13(8):525–41.

147. Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20.

148. Till BG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940–50.

149. Sazer A, et al. T cell-activating mesenchymal stem cells as a biorepository for HCC. Mol Ther Oncolytics. 2017;6:69–79.

150. Gao H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014;20(24):6418–28.

151. Jiang Z, et al. Anti-GPC-3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol. 2016:6790.

152. Yu M, et al. Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther. 2018;26(2):366–78.

153. Jiang W, et al. H1L-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo. Immunobiology. 2014;219(7):547–53.

154. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials. 2008;3(1):31–9.

155. Greten TF, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010;10:209.

156. Sawada Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res. 2012;18(13):3686–96.

157. Butterfield LH, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003;9(16 Pt 1):5902–8.

158. Park BH, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533–42.

159. Heo J, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19(3):329–36.

160. Makarova-Rusher OV, et al. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62(6):1420–9.

161. Alisa A, et al. Analysis of CD4+ T-cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res. 2005;11(16):6864–9.

162. Tada Y, et al. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican3-derived peptide. Int J Oncol. 2013;43(4):1019–26.

163. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for cancer immunotherapy. Cancer Sci. 2009;100(11):2044–21.

164. Jager E, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A. 2006;103(39):14453–8.

165. Chen JL, et al. NY-ESO-1-specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. Int J Cancer. 2015;136(6):6590–601.

166. Kim SH, et al. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung. 2009;187(6):401–11.

167. Nakamura S, et al. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21(8):1281–5.

168. Hong Y, et al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology. 2014;59(4):1448–58.

169. Liu TC, Kim D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 2007;67(2):429–32.

170. Chiocca EA, Rakbin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295–300.

171. Jiang H, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous Cancer vaccination. Cancer Res. 2017;77(14):3894–907.

172. He LF, et al. Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma. J Gene Med. 2008;10(9):983–92.

173. Wang Y, et al. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. J Gene Med. 2008;10(5):518–26.

174. Cerullo V, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumor immunity in cancer patients. Cancer Res. 2010;70(11):4297–303.

175. Heo J, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther. 2011;19(6):1170–9.

176. Hwang TH, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-therapeutic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19(10):1913–22.

177. Khan O, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211–8.

178. Schapar NE, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45(2):374–88.

179. Kim HD, et al. 4-1BB delineates distinct activation status of exhausted tumor-infiltrating CD8(+) T cells in culture. Nature. 2019;571(7764):211–8.

180. Lee JS, et al. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. Cell. 2018;174(6):1559–70 e22.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.